Liquid Biopsy Market Worth US$ 8,123.85 million by 2027 | Biocept, LungLife AI, Inivata, MDxHealth

Liquid biopsy is a revolutionary technology that is opening up various perspectives. The technology consists of isolation and detection of circulating tumor cells, tumor DNA and exosomes, which provides genomic information of the cancer patients. Liquid biopsy is used in cancer diagnosis in order to study the response or resistance to given treatments.Different samples used for liquid biopsy are blood, urine, and other samples which includes stool and others. Additionally, circulating tumor cells (ctc), exosomes, and free nucleic acid are the circulating biomarkers used for detection of cancers.

Based on product and services the liquid biopsy market is segmented into equipment, reagents & kits and services. The reagents & kits segment held the largest share of the market in 2019 and the same segment is anticipated to register the highest CAGR in the market during the forecast period.

Download Sample PDF Report Copy at:  https://www.theinsightpartners.com/sample/TIPRE00003996/

Biocept, inc., Bio-Rad Laboratories, Inc., Lunglifeai, inc, Exosome Diagnostics, F. Hoffmann-la Roche ltd, Inivata ltd,Exact sciences corporation, Mdxhealth, Qiagen, and Thermo fisher scientific inc. are among the key players present in the liquid biopsy market.

The companies are focused on following organic strategies such as product launches and business expansions to sustain their position in the dynamic market. For instance, in November 2019, Thermo Fisher Scientific launched a product namely Oncomine Precision Assay, which is innovative pan-cancer panel for the Genexus platform. It is likely to perform, genomic profiling from formalin-fixed, paraffin-embedded (FFPE) tissue and liquid biopsy samples with a single assay.

The liquid biopsy test is conducted to detect cancer at an early stage. The test is performed either on a blood sample to identify cancer cells present in the in blood stream, or on the DNA extracted from tumor cells. The government for early detection of cancer takes various initiatives. For instance, the National Institutes of Health (NIH) started a new initiative called Precompetitive Collaboration on liquid biopsy for early cancer assessment. The purposes of this initiative are to establish a Public-Private Partnership Program for the development of new or validate existing technologies, methods, and assays for the capture and quantification of tumor-associated cells, RNA, DNA, or exosomes in body fluids of patients with an early-stage disease or those at high risk. This initiative emphasis early cancer detection by distinguishing aggressive and  nonaggressive cancers, and differentiates benign disease from cancer.

The NCI'scommitment of funds towards R&D of clinical advanced technology will encourage the investigators to expand their research for early detection of cancer and accelerate clinical adoption of these promising technologies.

This research provides detailed information regarding the major factors influencing the growth of the Liquid Biopsy Market in Global and Regional Level (drivers, restraints, opportunities, and challenges), forecast of the market size, in terms of value, market share by region and segment; regional market positions; segment and country opportunities for growth; New product developments, strengths and weaknesses, brand portfolio; Marketing and distribution strategies; challenges and threats from current competition and prospects; Key company profiles, SWOT, product portfolio and growth strategies.

The research provides answers to the following key questions:

1.What is the estimated growth rate of the market for the forecast period 2020–2027? What will be the market size during the estimated period?
2. What are the key driving forces responsible for shaping the fate of the Liquid Biopsy market during the forecast period?
3. Who are the major market vendors and what are the winning strategies that have helped them occupy a strong foothold in the Liquid Biopsy market?
4. What are the prominent market trends influencing the development of the Liquid Biopsy market across different regions?
5. What are the major threats and challenges likely to act as a barrier in the growth of the Liquid Biopsy market
6. What are the major opportunities the market leaders can rely on to gain success and profitability?

Buy Complete Report at: https://www.theinsightpartners.com/buy/TIPRE00003996/

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com